StockData

Ginkgo Bioworks vs Regenxbio

DNA and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DNA and RGNX compare

Ginkgo Bioworks is the larger company, worth 1.2 times as much as Regenxbio ($560M against $478M).

Regenxbio grew revenue faster over the last twelve months (12.0% versus −46.8% for Ginkgo Bioworks).

Regenxbio keeps more of each dollar of sales as profit, with a net margin of −113% compared with −260% at Ginkgo Bioworks.

Ginkgo Bioworks scores higher on the StockData Score (9 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDNARGNX
Size and price
Market cap$560M$478M
Share price$8.32$7.24
Change, 1 year3.6%−37.1%
Change, 5 years−98.3%−76.6%
Beta (5Y)2.292.63
Employees485371
StockData Score
Total score9 (better)4
Valuation score2 (better)0
Growth score02 (better)
Performance score2 (better)1
Health score5 (better)1
Dividend score00
Valuation
P/S5.0×2.7× (better)
P/B1.3× (better)6.7×
FCF yield−31.2% (better)−52.2%
Fair value$9.57–
Margin of safety13.1%–
Growth
Revenue growth (TTM)−46.8%12.0% (better)
Revenue growth, 5Y average17.3% (better)2.0%
Profitability
Operating margin−260%−94.1% (better)
Net margin−260%−113% (better)
FCF margin−156%−143% (better)
Return on equity−56.3% (better)−138%
Return on invested capital−118%–
Financial health
Debt / equity0.00–
Interest coverage–−3.9×
Current ratio4.57 (better)2.86
Altman Z-score−8.83−3.88 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.7%64.2%
Held by insiders–7.6%
Insider net buying, 12 months−$5.0M$9.6K (better)
Superinvestors holding1–
Short interest, % of float–16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.